- Dollar Amount of Shares Purchased
- $4,171,890.31
- Number of Insider Purchases in the Last 180 Days
- 8
- Volume of Shares Purchased
- 1,280,405
- Who Bought Shares
- Brian Kenneth Roberts (Insider), Daron Evans (CFO), Nerissa Kreher (Director), Nevan C Elam (CEO), Wladimir Hogenhuis (Director) and Young-Jin Kim (Director)
About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
More about Rezolute